-
公开(公告)号：US20220203023A1
公开(公告)日：2022-06-30
申请号：US17514336
申请日：2021-10-29
Applicant: Insulet Corporation
Inventor： Jason O'CONNOR , Joon Bok LEE , David NAZZARO , Yibin ZHENG , Pauline TANDON
Abstract: A system for automatically delivering medication to a user is disclosed. A sensor worn by the user can collect information regarding the user. A user device, for example, a smartphone, executes a user application that uses the collected information to determine an amount of medication to provide to the user. The user application includes a graphical user interface that allows the user to easily interact with the user application to specify various aspects of the delivery of the medication. The user application controls a wearable drug delivery device to dispense the medication to the user.
-
公开(公告)号：US20220062548A1
公开(公告)日：2022-03-03
申请号：US17406209
申请日：2021-08-19
Applicant: Insulet Corporation
Inventor： Yibin ZHENG , Rangarajan NARAYANASWAMI , Joon Bok LEE
Abstract: Disclosed are systems, devices, methods and computer-readable medium products that compensate for consumption of a meal by providing a reduced-constraint meal bolus dosage. The reduced-constraint meal bolus dosage is determined using post-prandial safety constraints that are reduced based on an indication that a meal has been consumed. The post-prandial safety constraints are intended to protect users from overdelivering or underdelivering insulin to the user. The determinations may be performed by a control algorithm-based drug delivery system that enables automatic delivery of a drug, such as insulin or the like.
-
公开(公告)号：US20220062546A1
公开(公告)日：2022-03-03
申请号：US17008101
申请日：2020-08-31
Applicant: Insulet Corporation
Inventor： Eric BENJAMIN , Jason O'CONNOR , Yibin ZHENG , Joon Bok LEE , Mark BOYNS
IPC: A61M5/172 , G16H50/30 , G16H40/40 , G16H40/67 , G16H50/20 , G16H50/70 , G16H10/60 , G16H20/13 , G06F9/445
Abstract: The exemplary embodiments allow a user to have more aggressive settings or less aggressive settings for an AID system after demonstrating good blood glucose level control. This allows the settings to be more quickly customized to users that demonstrate good quality blood glucose level control than conventional systems. As these users have demonstrated good quality glucose level control there is less of a need to constrain the settings and provide a high margin of safety. Conversely, users demonstrating poor quality blood glucose level control may have less aggressive settings imposed, representing a higher margin of safety.
-
公开(公告)号：US20220062542A1
公开(公告)日：2022-03-03
申请号：US17412666
申请日：2021-08-26
Applicant: Insulet Corporation
Inventor： David NAZZARO , Jason O'CONNOR , Ian MCLAUGHLIN , Philip HILLDALE , Joon Bok LEE , Bret CHRISTENSEN , Maureen MCCAFFREY , Thomas METZMAKER
Abstract: Embodiments of the present disclosure relate to techniques, processes, devices or systems for automating fluid delivery without the use of an external interface device. In one approach, a wearable drug delivery device may include a reservoir configured to store a liquid drug, a pump mechanism coupled to the reservoir and operable to expel the liquid drug from the reservoir, and a mechanical triggering device engageable by a user. The mechanical triggering device is operable to change between a first configuration and a second configuration to control deployment of a needle to deliver the liquid drug into a patient.
-
公开(公告)号：US20220023536A1
公开(公告)日：2022-01-27
申请号：US17377801
申请日：2021-07-16
Applicant: Insulet Corporation
Inventor： James GRAHAM , Joon Bok LEE , Jason O'CONNOR
Abstract: Disclosed are techniques and a device operable to determine a total amount of insulin delivered to the user over a predetermined time period. The total amount of insulin includes a total basal dosage delivered in basal dosages and a total bolus dosage delivered in bolus dosages over the predetermined time period. A proportion of the total amount of insulin delivered to the user provided via the total basal dosage amount over the predetermined time period is calculated. In response determining the proportion of the total amount of insulin attributed to the total basal dosage amount of insulin exceeds a threshold, an average basal dosage to be delivered within a subsequent time period that is approximately equal to the threshold may be determined. An instruction may be generated and output to deliver a modified basal dosage that substantially maintains the average basal dosage over the subsequent time period.
-
Patent Agency Ranking
公开(公告)号：US20210313037A1
公开(公告)日：2021-10-07
申请号：US16840603
申请日：2020-04-06
Applicant: INSULET CORPORATION
Inventor： Jason O'CONNOR , Ian MCLAUGHLIN , Daniel ALLIS , Paul Frederick BENTE, IV , Steven CARDINALI , Joon Bok LEE
Abstract: A system, techniques, and computer-readable media includes examples that provide an indication of an early exercise detection are described. An example of an early exercise detection application executed by a processor may cause the processor to perform functions and be operable to obtain image data including metadata from a camera of a mobile device during, for example, an unlock procedure of a mobile device. The processor may determine whether the obtained image data includes location or timestamp information in metadata or has image data that may be recognized as exercise-related objects. Based on the determinations, the processor may output an indication of early exercise detection to an artificial pancreas application, which is operable to adjust an amount of insulin to be delivered to a user.
-
37.发明申请公开(公告)号：US20210244880A1
公开(公告)日：2021-08-12
申请号：US16788892
申请日：2020-02-12
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Ashutosh ZADE , Jason O'CONNOR , Trang LY , Yibin ZHENG , Connor GULLIFER , Kyle GROVER
Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.
-
公开(公告)号：US20210205535A1
公开(公告)日：2021-07-08
申请号：US17142425
申请日：2021-01-06
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR
Abstract: Exemplary embodiments provide an approach to predicting meal and/or exercise events for an insulin delivery system that otherwise does not otherwise identify such events. The insulin delivery system may use a model of glucose insulin interactions that projects estimated future glucose values based on the history of glucose values and insulin deliveries for the user. The predictions of meal events and/or exercise events may be based on residuals between actual glucose values and predicted glucose values. The exemplary embodiments may calculate a rate of change of the residuals over a period of time and compare the rate of change to thresholds to determine whether there likely has been a meal event or an exercise event. The insulin delivery system may then take measures to account for the meal or exercise by the user.
-
公开(公告)号：US20210128831A1
公开(公告)日：2021-05-06
申请号：US17085344
申请日：2020-10-30
Applicant: Insulet Corporation
Inventor： Ashutosh ZADE , Joon Bok LEE , Yibin ZHENG , Rangarajan NARAYANASWAMI , David NAZZARO , Thomas METZMAKER
Abstract: A wearable drug delivery device and method for optimizing performance thereof are provided. A system may include a processor operable with memory, and a drug delivery device and sensor coupled to a user, the sensor operable to detect characteristics of the delivery device. A receiver operable on the processor receives an input signal from the sensor, the input signal representing the detected characteristics. A controller operable on the processor receives the input signal from the receiver, and retrieves, from memory, a baseline characteristics. The controller may determine a location of the delivery device and a tissue profile of the injection location based on a comparison between the detected characteristics and the baseline characteristics. The controller may further control or modify delivery of a liquid drug from the delivery device in response to the location of the delivery device.
-
40.发明申请公开(公告)号：US20250144295A1
公开(公告)日：2025-05-08
申请号：US19017941
申请日：2025-01-13
Applicant: INSULET CORPORATION
Inventor： Yibin ZHENG , Joon Bok LEE , Ashutosh ZADE , Jason O'CONNOR
Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.
-
-
-
-
-
-
-
-
-
Search Results
111
records
(took 0.021 seconds)
